CodeMap® 

11/18/2021 2020 Part B Utilization Data Loaded
150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule

2022
2021

Physician Fee Schedule

2022
2021

OPPS Fee Schedule

2022-January
2021-October

ASC Fee Schedule

2022-January
2021-October

APC Codes

2022-January
2021-October

DRG Codes

2022
2021

ASP Drug Pricing Files

January 2022
October 2021


CMS Transmittals



Shipping update: 2022 CodeMap Manuals beginning shipping 1/19. All orders will be shipped by January 31.


CodeMap® Compliance Briefing: 4/17/09


Editor's Welcome:

Comparative effectiveness (CE) has become a popular buzzword in Washington and may play an important part in healthcare reform efforts. CE studies are designed to compare multiple tests or treatments to determine which is the most effective in terms of clinical outcomes. Due to regulatory constraints, costs may not be considered in a given study. However, tests or procedures that are both cost effective, as well as clinically effective will be the most likely to be included in future treatment guidelines and coverage policy. Today, we will define various aspects of CE studies, the dramatically increased funding now available for such investigations, and the impact these studies may have on Medicare coverage and reim....

Sorry, the full document you are trying to access requires an active subscription.

Please login to the left.


Click here for publications catalog.

--

CodeMap® is a Registered Trademark of Wheaton Partners, LLC.